An authoritative scientific review of the BPC-157 sequence, its angiogenic mechanisms, molecular stability, and established research protocols since 2019.
BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide composed of 15 amino acids. Derived from a protective protein found in human gastric juice, this sequence has been a primary focus of regenerative research since the early 1990s. Its unique molecular structure is characterized by a remarkable resistance to enzymatic degradation, a quality often referred to in literature as “gastric stability.”
Unlike many other bioactive peptides that degrade rapidly in the presence of stomach acid or protease enzymes, BPC-157 maintains its structural integrity. This stability has made it a subject of intense study for gastrointestinal repair, tendon-to-bone healing, and systemic anti-inflammatory research. At PeptidesLtd.com, we have tracked the evolution of BPC-157 data since 2019, observing a consistent trend toward its role as a master regulator of the healing cascade.
In a laboratory setting, BPC-157 is primarily studied for its ability to accelerate angiogenesis—the formation of new blood vessels from pre-existing ones. This mechanism is central to its regenerative potential, as it ensures that oxygen and nutrients are efficiently delivered to site-specific research models.
| Property | Technical Specification |
|---|---|
| Amino Acid Sequence | Gly-Pro-Pro-Leu-Asp-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val |
| Molecular Formula | C62H98N16O22 |
| Molecular Weight | 1419.53 g/mol |
| CAS Number | 137525-51-0 |
| Purity Benchmark | >99% (Research Grade) |
| Stability | Highly Stable (Gastric & Aqueous) |
The biological activity of BPC-157 is multifaceted. While its most prominent feature is the up-regulation of Vascular Endothelial Growth Factor (VEGF), its influence extends to several other critical signaling pathways.
BPC-157 triggers the formation of new blood vessels by activating the VEGF signaling pathway. This is not just a general increase in vessel count; research indicates that BPC-157 promotes a more organized and robust vascular network. This “angiogenic rescue” is particularly evident in models of vascular damage or impaired circulation.
Fibroblasts are the primary cells responsible for collagen synthesis. BPC-157 has been shown to enhance the migration and proliferation of fibroblasts. By increasing the expression of growth hormone receptors on these cells, the peptide indirectly promotes faster tissue remodeling and stronger extracellular matrix density.
BPC-157 interacts with the Nitric Oxide system, helping to regulate blood pressure and promote endothelial health. It acts as an NO-modulator, protecting the endothelium against various stressors and ensuring a balanced vasodilatory response in research subjects.
Research Note: Unlike TB-500, which focuses on G-actin sequestering and cellular migration, BPC-157’s primary strength lies in its ability to modulate the healing environment itself—promoting vessel growth and stabilizing the nitric oxide pathway. In many synergistic research models, these two peptides are studied together to observe a dual-action healing response.
The “gastric stability” of BPC-157 is its defining chemical characteristic. In a study comparing various growth factors, BPC-157 remained active in simulated gastric juice for over 24 hours, whereas other regenerative molecules degraded within minutes. This stability is attributed to its cyclic-like properties and specific amino acid arrangement.
For research purposes, BPC-157 is typically synthesized via Solid Phase Peptide Synthesis (SPPS). Given its 15-amino acid length, achieving high purity is relatively straightforward for advanced laboratories. However, PeptidesLtd.com emphasizes that researchers must verify the salt form of the peptide. BPC-157 is most stable as an Acetate salt, though some lower-grade versions use TFA (Trifluoroacetic acid), which can be more acidic and less suitable for certain sensitive biological models.
It is critical to emphasize that BPC-157 is intended for laboratory research only. The following data points reflect dosages observed in peer-reviewed animal and in-vitro studies. These are not human recommendations.
Per kg of body weight in typical rodent models for systemic repair.
Daily systemic dosage observed in acute ligament injury research.
Maintains efficacy when administered via drinking water in GI models.
The most common route of administration in research is subcutaneous injection, which allows for high systemic bioavailability. However, due to its stability, oral administration (often via the Arginate salt form) is a growing area of study for chronic inflammatory bowel research.
Since our launch in 2019, we have analyzed over 100 studies concerning BPC-157. The following areas represent the most robust data sets:
Acetate is the standard salt form used in most injectable research. Arginate (Stable BPC) is a newer salt form specifically engineered for even higher stability in the digestive tract, making it the preferred choice for oral bioavailability studies.
Lyophilized BPC-157 should be kept in a freezer at -20°C for long-term storage. Once reconstituted with bacteriostatic water, it should be refrigerated at 2°C to 8°C and used within 21 to 28 days to prevent degradation and maintain research fidelity.
While not a steroid, BPC-157 was added to the World Anti-Doping Agency (WADA) prohibited list in 2022 under the category of “Non-approved substances.” This is a critical consideration for any research involving competitive athletes.
Because BPC-157 is often used in models of inflammation and repair, manufacturing contaminants (like residual TFA) can trigger unwanted immune responses, effectively masking the peptide’s true effects. Verification via HPLC (>99% purity) is essential.
For researchers seeking the raw data and clinical trials, we recommend the following sources:
Explore the synergistic effects of BPC-157 when paired with other regenerative sequences like TB-500.
Study TB-500 MechanismLast Updated: January 2026 | Verified by PeptidesLtd Research Team | Since 2019
